Physicochemical Properties
| Molecular Formula | C25H25N7O4 |
| Molecular Weight | 487.5105 |
| Exact Mass | 487.196 |
| CAS # | 2093387-77-8 |
| PubChem CID | 131988582 |
| Appearance | Light yellow to yellow solid powder |
| LogP | 4.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 36 |
| Complexity | 817 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O(C([H])([H])[H])C1=C(C2C(C([H])([H])[H])=NOC=2C([H])([H])[H])C([H])=C2C(=C1[H])C1=C(N=C(C(=O)O[H])N=C1N([H])C1=C([H])C(C3([H])C([H])([H])C3([H])[H])=NN1C([H])([H])C([H])([H])[H])N2[H] |
| InChi Key | DSICVZUZCUHARI-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C25H25N7O4/c1-5-32-19(10-16(30-32)13-6-7-13)27-23-21-14-9-18(35-4)15(20-11(2)31-36-12(20)3)8-17(14)26-22(21)28-24(29-23)25(33)34/h8-10,13H,5-7H2,1-4H3,(H,33,34)(H2,26,27,28,29) |
| Chemical Name | 4-[(5-cyclopropyl-2-ethylpyrazol-3-yl)amino]-7-(3,5-dimethyl-1,2-oxazol-4-yl)-6-methoxy-9H-pyrimido[4,5-b]indole-2-carboxylic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | The proteins known as the bromodomain and extra-terminal (BET) family, which includes the testis-specific BRDT members, BRD2, BRD3, and BRD4 are known as epigenetic "readers" and are important in controlling gene transcription. In order to treat cancer and other human disorders, BET proteins are thought to be appealing therapeutic targets[1]. |
| References |
[1]. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~50 mg/mL (~102.56 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.13 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0512 mL | 10.2562 mL | 20.5124 mL | |
| 5 mM | 0.4102 mL | 2.0512 mL | 4.1025 mL | |
| 10 mM | 0.2051 mL | 1.0256 mL | 2.0512 mL |